Le Lézard
Classified in: Health
Subjects: RCL, CFG

Food Recall Warning - Pacific Rim Shellfish (2003) Corp brand Oysters recalled due to norovirus


OTTAWA, ON, March 27, 2022 /CNW/ -

Product photos are available: https://recalls-rappels.canada.ca/en/alert-recall/pacific-rim-shellfish-2003-corp-brand-oysters-recalled-due-norovirus

Summary
Affected products

Brand

Product

Size

UPC

Codes

Pacific Rim
Shellfish (2003)
Corp

XSM Tray
Oyster

Variable
(clerk-served)

None

Harvest Location BC 14-15

Lease # 1400036

 

Harvest Date:

  • March 9, 2022,
  • March 15, 2022, &
  • March 19, 2022

 

Pacific Rim
Shellfish (2003)
Corp

XSM Beach
Oyster

Variable
(clerk-served)

None

Harvest Area BC 14-15

Lease # 1400036

Harvest Date:

  • March 9, 2022 &
  • March 15, 2022

 

Pacific Rim
Shellfish (2003)
Corp

MLarge Tray
Oyster

Variable
(clerk-served)

None

Harvest Area BC 14-15

Lease # 1400036

Harvest Date: March 9, 2022

 

Pacific Rim
Shellfish (2003)
Corp

MLarge Beach
Oyster

Variable
(clerk-served)

None

Harvest Area BC 14-15

Lease # 1400036

Harvest Date: March 15, 2022

 

Issue

Pacific Rim Shellfish (2003) Corporation is recalling Pacific Rim Shellfish (2003) Corp brand Oysters from the marketplace due to possible norovirus contamination.

The recalled products have been sold in British Columbia, Alberta, Saskatchewan, Manitoba, Yukon, and Ontario and may have been distributed in other provinces and territories.

What you should do

People with norovirus illness usually develop symptoms of gastroenteritis within 24 to 48 hours, but symptoms can start as early as 12 hours after exposure. The illness often begins suddenly. Even after having the illness, you can still become re-infected by norovirus. The main symptoms of norovirus illness are diarrhea, vomiting (children usually experience more vomiting than adults), nausea and stomach cramps. Other symptoms may include low-grade fever, headache, chills, muscle aches and fatigue (a general sense of tiredness).  Most people feel better within one or two days, with symptoms resolving on their own, and experience no long-term health effects. As with any illness causing diarrhea or vomiting, people who are ill should drink plenty of liquids to replace lost body fluids and prevent dehydration. In severe cases, patients may need to be hospitalized and given fluids intravenously.

Learn more:

Background

This recall was triggered by findings of the Canadian Food Inspection Agency during its investigation into a foodborne illness outbreak.

There have been reported illnesses associated with the consumption of these products.

What is being done

The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated food recall warnings.

The CFIA is verifying that industry is removing the recalled products from the marketplace.

Également disponible en français

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: